ZzzQuil Should Not Be Used for Chronic Insomnia Treatment
The American Academy of Sleep Medicine explicitly recommends against using diphenhydramine (the active ingredient in ZzzQuil) for treating insomnia in adults. 1 This recommendation is based on evidence showing minimal sleep improvement (only 8-12 minutes reduction in sleep latency and total sleep time) with no improvement in sleep quality compared to placebo.
FDA-Approved Dosing (If Use is Unavoidable)
According to the FDA label, if you must use ZzzQuil 2:
- Adults and children ≥12 years: 30 mL (50 mg diphenhydramine HCl) at bedtime
- Take only once per 24 hours
- Do NOT use in children under 12 years
- Do NOT combine with any other diphenhydramine-containing products
Why This Recommendation Exists
The 2017 American Academy of Sleep Medicine guidelines 1 found that diphenhydramine at 50 mg doses showed:
- Mean sleep latency reduction of only 8 minutes vs placebo
- Total sleep time improvement of only 12 minutes vs placebo
- No improvement in quality of sleep
- Significant anticholinergic side effects
This minimal benefit does not justify the risks, especially when compared to evidence-based alternatives.
Better Alternatives
The 2020 VA/DoD guidelines 3 and 2017 AASM guidelines 1 recommend the following hierarchy:
- First-line: Cognitive Behavioral Therapy for Insomnia (CBT-I) - Superior long-term outcomes with no adverse effects
- If pharmacotherapy needed:
- Low-dose doxepin (3-6 mg) for sleep maintenance
- Non-benzodiazepine BZRAs (zolpidem 10 mg, eszopiclone 2-3 mg) for short-term use
- These show 28-57 minutes improvement in total sleep time vs 12 minutes for diphenhydramine
Critical Safety Concerns
Recent 2025 evidence 4 calls for diphenhydramine to be removed from widespread availability due to:
- Higher adverse effects in children and older adults
- Anticholinergic toxicity (confusion, urinary retention, tachycardia)
- Paradoxical excitation in children
- Cognitive impairment and fall risk in elderly
- Countries like Germany and Sweden have already restricted first-generation antihistamines
When Short-Term Use Might Be Acceptable
The only scenario where diphenhydramine may be considered is acute, short-term insomnia (1-2 nights) in healthy adults without contraindications 5. However, even for acute insomnia, second-generation antihistamines or prescription alternatives are preferred.
Contraindications to avoid:
- Age >65 years (increased anticholinergic sensitivity)
- Benign prostatic hyperplasia
- Narrow-angle glaucoma
- Cognitive impairment or dementia risk
- Concurrent anticholinergic medications
- Children <12 years (FDA contraindication) 2
Common Pitfalls
- Do not use for chronic insomnia - The evidence shows it doesn't work and guidelines explicitly recommend against it 1
- Do not use nightly - Tolerance develops rapidly, and anticholinergic burden accumulates
- Do not exceed 50 mg/day - Higher doses increase toxicity without improving efficacy 2
- Avoid in elderly - Despite OTC availability, diphenhydramine is on the Beers Criteria as potentially inappropriate for older adults
The 10% alcohol content in ZzzQuil liquid formulation 2 adds another reason to avoid this product, particularly in patients with liver disease, those taking other CNS depressants, or anyone concerned about alcohol exposure.